Overall survival and toxicity of Y90 radioembolization for hepatocellular carcinoma patients in Barcelona Clinic Liver Cancer stage C (BCLC-C)

Pulak Goswami; Oladapo R. Adeniran; Shelby K. Frantz; Lea Matsuoka; Liping Du; Ripal T. Gandhi; Zachary S. Collins; Marc R. Matrana; Michael Petroziello; Jayson S. Brower; Daniel Y. Sze; Andrew S. Kennedy; Jafar Golzarian; Eric A. Wang; Daniel B. Brown

doi:10.1186/s12876-022-02528-y

Overall survival and toxicity of Y90 radioembolization for hepatocellular carcinoma patients in Barcelona Clinic Liver Cancer stage C (BCLC-C)

Pulak Goswami, Oladapo R. Adeniran, Shelby K. Frantz, Lea Matsuoka, Liping Du, Ripal T. Gandhi, Zachary S. Collins, Marc R. Matrana, Michael Petroziello, Jayson S. Brower, Daniel Y. Sze, Andrew S. Kennedy, Jafar Golzarian, Eric A. Wang, Daniel B. Brown

Radiology

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

INTRODUCTION: National Comprehensive Cancer Network HCC guidelines recommend Y90 to treat BCLC-C patients only in select cases given the development of systemic regimens. We sought to identify ideal candidates for Y90 by assessing survival and toxicities in this patient group.

MATERIALS AND METHODS: The Radiation-Emitting Selective Internal radiation spheres in Non-resectable tumor registry is a prospective observational study (NCT: 02,685,631). Patients with advanced HCC were stratified into 3 groups based on tumor location, Eastern Cooperative Oncology Group (ECOG) performance status, and liver function. Group 1: liver isolated HCC, ECOG 0 and Child Pugh (CP) A (n = 12, 16%), Group 2: liver isolated HCC, ECOG ≥ 1 or CP B/C (n = 37, 49%), and Group 3: extrahepatic HCC with any ECOG or CP score (n = 26, 35%). Patients in any group could have macrovascular invasion. Overall survival (OS) and progression-free survival (PFS) with 95% confidence intervals (95% CI) were calculated. Grade 3 + toxicities were tracked using Common Terminology Criteria for Adverse Events v5. Cox proportional hazard model was performed to determine factors affecting OS.

RESULTS: Seventy-five BCLC-C patients treated between 2015 and 2019 were reviewed. The groups were similar in age, sex, race, and ethnicity (all p > 0.05). Bilobar disease was least common in Group 1 (p < 0.001). Median OS of the entire cohort was 13.6 (95% CI 7.5-16.1) months. Median OS of Groups 1-3 were 21.8, 13.1 and 11.5 months respectively (p = 0.6). Median PFS for the cohort was 6.3 (4.8-14.7) months. Median PFS for group 1 was not reached. Mean PFS for Group 1 was 17.3 ± 4.8 months. Median PFS for Groups 2 and 3 was 6.8 and 5.9 months (X 2 = 1.5, p = 0.5). Twenty-four Grade 3 or greater toxicities developed, most commonly hyperbilirubinemia (8/75, 11%) and thrombocytopenia (2/75, 3%). The incidence of toxicities between groups was similar (all p > 0.05). Cox Proportional Hazard analysis predicted shorter OS with CP class B/C (X 2 = 6.7, p = 0.01), while macrovascular invasion (X 2 = 0.5, p = 0.5) and ECOG score of ≥ 1 (X 2 = 2.1, p = 0.3) was not associated with OS.

CONCLUSIONS: OS of CPA patients with advanced HCC and performance status of 0 was 21.8 months following Y90. CP A cirrhosis is the best predictor of prolonged OS in advanced (BCLC-C) HCC.

Original language	English (US)
Article number	467
Journal	BMC Gastroenterology
Volume	22
Issue number	1
DOIs	https://doi.org/10.1186/s12876-022-02528-y
State	Published - Dec 2022

Bibliographical note

Funding Information:
Ripal T. Gandhi is a consultant and speaker for Sirtex Medical and serves as a proctor for Sirtex Medical. Zachary S. Collins has received an institutional research grant from Sirtex Medical and serves as a speaker and consultant for Sirtex Medical. Jayson S. Brower is a consultant for Sirtex Medical. Daniel Y. Sze has received institutional research grants from Sirtex Medical and Boston Scientific. He was a consultant and has received support for travel/hotel/meals for meetings with Sirtex Medical and Boston Scientific. Andrew S. Kennedy has received institutional support from Sirtex Medical. Jafar Golzarian is a consultant for Sirtex Medical and Boston Scientific. He has also received institutional grant support from Sirtex Medical. Eric A. Wang is a proctor for Sirtex Medical. Daniel B. Brown has received institutional research support from Sirtex Medical and Guerbet. He has served as a speaker for Cook Medical and a Data Safety Monitor for Bard Medical. The other authors do not have a conflict to report.

Publisher Copyright:
© 2022, The Author(s).

Keywords

Adult
Carcinoma, hepatocellular carcinoma
Treatment outcome
Yttrium radioisotopes/ adverse events
Yttrium radioisotopes/ therapeutic use
Liver Neoplasms/pathology
Carcinoma, Hepatocellular/pathology
Humans
Progression-Free Survival
Proportional Hazards Models
Cohort Studies

PubMed: MeSH publication types

Observational Study
Journal Article

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1186/s12876-022-02528-y

Find It

Find It at U of M Libraries

Cite this

Goswami, P., Adeniran, O. R., K. Frantz, S., Matsuoka, L., Du, L., Gandhi, R. T., Collins, Z. S., Matrana, M. R., Petroziello, M., Brower, J. S., Sze, D. Y., Kennedy, A. S., Golzarian, J., Wang, E. A., & Brown, D. B. (2022). Overall survival and toxicity of Y90 radioembolization for hepatocellular carcinoma patients in Barcelona Clinic Liver Cancer stage C (BCLC-C). BMC Gastroenterology, 22(1), Article 467. https://doi.org/10.1186/s12876-022-02528-y

Goswami, P, Adeniran, OR, K. Frantz, S, Matsuoka, L, Du, L, Gandhi, RT, Collins, ZS, Matrana, MR, Petroziello, M, Brower, JS, Sze, DY, Kennedy, AS, Golzarian, J, Wang, EA & Brown, DB 2022, 'Overall survival and toxicity of Y90 radioembolization for hepatocellular carcinoma patients in Barcelona Clinic Liver Cancer stage C (BCLC-C)', BMC Gastroenterology, vol. 22, no. 1, 467. https://doi.org/10.1186/s12876-022-02528-y

@article{b3aa2d6592f14db78512318fcca4a880,

title = "Overall survival and toxicity of Y90 radioembolization for hepatocellular carcinoma patients in Barcelona Clinic Liver Cancer stage C (BCLC-C)",

abstract = "INTRODUCTION: National Comprehensive Cancer Network HCC guidelines recommend Y90 to treat BCLC-C patients only in select cases given the development of systemic regimens. We sought to identify ideal candidates for Y90 by assessing survival and toxicities in this patient group.MATERIALS AND METHODS: The Radiation-Emitting Selective Internal radiation spheres in Non-resectable tumor registry is a prospective observational study (NCT: 02,685,631). Patients with advanced HCC were stratified into 3 groups based on tumor location, Eastern Cooperative Oncology Group (ECOG) performance status, and liver function. Group 1: liver isolated HCC, ECOG 0 and Child Pugh (CP) A (n = 12, 16%), Group 2: liver isolated HCC, ECOG ≥ 1 or CP B/C (n = 37, 49%), and Group 3: extrahepatic HCC with any ECOG or CP score (n = 26, 35%). Patients in any group could have macrovascular invasion. Overall survival (OS) and progression-free survival (PFS) with 95% confidence intervals (95% CI) were calculated. Grade 3 + toxicities were tracked using Common Terminology Criteria for Adverse Events v5. Cox proportional hazard model was performed to determine factors affecting OS.RESULTS: Seventy-five BCLC-C patients treated between 2015 and 2019 were reviewed. The groups were similar in age, sex, race, and ethnicity (all p > 0.05). Bilobar disease was least common in Group 1 (p < 0.001). Median OS of the entire cohort was 13.6 (95% CI 7.5-16.1) months. Median OS of Groups 1-3 were 21.8, 13.1 and 11.5 months respectively (p = 0.6). Median PFS for the cohort was 6.3 (4.8-14.7) months. Median PFS for group 1 was not reached. Mean PFS for Group 1 was 17.3 ± 4.8 months. Median PFS for Groups 2 and 3 was 6.8 and 5.9 months (X 2 = 1.5, p = 0.5). Twenty-four Grade 3 or greater toxicities developed, most commonly hyperbilirubinemia (8/75, 11%) and thrombocytopenia (2/75, 3%). The incidence of toxicities between groups was similar (all p > 0.05). Cox Proportional Hazard analysis predicted shorter OS with CP class B/C (X 2 = 6.7, p = 0.01), while macrovascular invasion (X 2 = 0.5, p = 0.5) and ECOG score of ≥ 1 (X 2 = 2.1, p = 0.3) was not associated with OS. CONCLUSIONS: OS of CPA patients with advanced HCC and performance status of 0 was 21.8 months following Y90. CP A cirrhosis is the best predictor of prolonged OS in advanced (BCLC-C) HCC.",

keywords = "Adult, Carcinoma, hepatocellular carcinoma, Treatment outcome, Yttrium radioisotopes/ adverse events, Yttrium radioisotopes/ therapeutic use, Liver Neoplasms/pathology, Carcinoma, Hepatocellular/pathology, Humans, Progression-Free Survival, Proportional Hazards Models, Cohort Studies",

author = "Pulak Goswami and Adeniran, {Oladapo R.} and {K. Frantz}, Shelby and Lea Matsuoka and Liping Du and Gandhi, {Ripal T.} and Collins, {Zachary S.} and Matrana, {Marc R.} and Michael Petroziello and Brower, {Jayson S.} and Sze, {Daniel Y.} and Kennedy, {Andrew S.} and Jafar Golzarian and Wang, {Eric A.} and Brown, {Daniel B.}",

note = "Funding Information: Ripal T. Gandhi is a consultant and speaker for Sirtex Medical and serves as a proctor for Sirtex Medical. Zachary S. Collins has received an institutional research grant from Sirtex Medical and serves as a speaker and consultant for Sirtex Medical. Jayson S. Brower is a consultant for Sirtex Medical. Daniel Y. Sze has received institutional research grants from Sirtex Medical and Boston Scientific. He was a consultant and has received support for travel/hotel/meals for meetings with Sirtex Medical and Boston Scientific. Andrew S. Kennedy has received institutional support from Sirtex Medical. Jafar Golzarian is a consultant for Sirtex Medical and Boston Scientific. He has also received institutional grant support from Sirtex Medical. Eric A. Wang is a proctor for Sirtex Medical. Daniel B. Brown has received institutional research support from Sirtex Medical and Guerbet. He has served as a speaker for Cook Medical and a Data Safety Monitor for Bard Medical. The other authors do not have a conflict to report. Publisher Copyright: {\textcopyright} 2022, The Author(s).",

year = "2022",

month = dec,

doi = "10.1186/s12876-022-02528-y",

language = "English (US)",

volume = "22",

journal = "BMC Gastroenterology",

issn = "1471-230X",

publisher = "BioMed Central",

number = "1",

}

TY - JOUR

T1 - Overall survival and toxicity of Y90 radioembolization for hepatocellular carcinoma patients in Barcelona Clinic Liver Cancer stage C (BCLC-C)

AU - Goswami, Pulak

AU - Adeniran, Oladapo R.

AU - K. Frantz, Shelby

AU - Matsuoka, Lea

AU - Du, Liping

AU - Gandhi, Ripal T.

AU - Collins, Zachary S.

AU - Matrana, Marc R.

AU - Petroziello, Michael

AU - Brower, Jayson S.

AU - Sze, Daniel Y.

AU - Kennedy, Andrew S.

AU - Golzarian, Jafar

AU - Wang, Eric A.

AU - Brown, Daniel B.

N1 - Funding Information: Ripal T. Gandhi is a consultant and speaker for Sirtex Medical and serves as a proctor for Sirtex Medical. Zachary S. Collins has received an institutional research grant from Sirtex Medical and serves as a speaker and consultant for Sirtex Medical. Jayson S. Brower is a consultant for Sirtex Medical. Daniel Y. Sze has received institutional research grants from Sirtex Medical and Boston Scientific. He was a consultant and has received support for travel/hotel/meals for meetings with Sirtex Medical and Boston Scientific. Andrew S. Kennedy has received institutional support from Sirtex Medical. Jafar Golzarian is a consultant for Sirtex Medical and Boston Scientific. He has also received institutional grant support from Sirtex Medical. Eric A. Wang is a proctor for Sirtex Medical. Daniel B. Brown has received institutional research support from Sirtex Medical and Guerbet. He has served as a speaker for Cook Medical and a Data Safety Monitor for Bard Medical. The other authors do not have a conflict to report. Publisher Copyright: © 2022, The Author(s).

PY - 2022/12

Y1 - 2022/12

N2 - INTRODUCTION: National Comprehensive Cancer Network HCC guidelines recommend Y90 to treat BCLC-C patients only in select cases given the development of systemic regimens. We sought to identify ideal candidates for Y90 by assessing survival and toxicities in this patient group.MATERIALS AND METHODS: The Radiation-Emitting Selective Internal radiation spheres in Non-resectable tumor registry is a prospective observational study (NCT: 02,685,631). Patients with advanced HCC were stratified into 3 groups based on tumor location, Eastern Cooperative Oncology Group (ECOG) performance status, and liver function. Group 1: liver isolated HCC, ECOG 0 and Child Pugh (CP) A (n = 12, 16%), Group 2: liver isolated HCC, ECOG ≥ 1 or CP B/C (n = 37, 49%), and Group 3: extrahepatic HCC with any ECOG or CP score (n = 26, 35%). Patients in any group could have macrovascular invasion. Overall survival (OS) and progression-free survival (PFS) with 95% confidence intervals (95% CI) were calculated. Grade 3 + toxicities were tracked using Common Terminology Criteria for Adverse Events v5. Cox proportional hazard model was performed to determine factors affecting OS.RESULTS: Seventy-five BCLC-C patients treated between 2015 and 2019 were reviewed. The groups were similar in age, sex, race, and ethnicity (all p > 0.05). Bilobar disease was least common in Group 1 (p < 0.001). Median OS of the entire cohort was 13.6 (95% CI 7.5-16.1) months. Median OS of Groups 1-3 were 21.8, 13.1 and 11.5 months respectively (p = 0.6). Median PFS for the cohort was 6.3 (4.8-14.7) months. Median PFS for group 1 was not reached. Mean PFS for Group 1 was 17.3 ± 4.8 months. Median PFS for Groups 2 and 3 was 6.8 and 5.9 months (X 2 = 1.5, p = 0.5). Twenty-four Grade 3 or greater toxicities developed, most commonly hyperbilirubinemia (8/75, 11%) and thrombocytopenia (2/75, 3%). The incidence of toxicities between groups was similar (all p > 0.05). Cox Proportional Hazard analysis predicted shorter OS with CP class B/C (X 2 = 6.7, p = 0.01), while macrovascular invasion (X 2 = 0.5, p = 0.5) and ECOG score of ≥ 1 (X 2 = 2.1, p = 0.3) was not associated with OS. CONCLUSIONS: OS of CPA patients with advanced HCC and performance status of 0 was 21.8 months following Y90. CP A cirrhosis is the best predictor of prolonged OS in advanced (BCLC-C) HCC.

AB - INTRODUCTION: National Comprehensive Cancer Network HCC guidelines recommend Y90 to treat BCLC-C patients only in select cases given the development of systemic regimens. We sought to identify ideal candidates for Y90 by assessing survival and toxicities in this patient group.MATERIALS AND METHODS: The Radiation-Emitting Selective Internal radiation spheres in Non-resectable tumor registry is a prospective observational study (NCT: 02,685,631). Patients with advanced HCC were stratified into 3 groups based on tumor location, Eastern Cooperative Oncology Group (ECOG) performance status, and liver function. Group 1: liver isolated HCC, ECOG 0 and Child Pugh (CP) A (n = 12, 16%), Group 2: liver isolated HCC, ECOG ≥ 1 or CP B/C (n = 37, 49%), and Group 3: extrahepatic HCC with any ECOG or CP score (n = 26, 35%). Patients in any group could have macrovascular invasion. Overall survival (OS) and progression-free survival (PFS) with 95% confidence intervals (95% CI) were calculated. Grade 3 + toxicities were tracked using Common Terminology Criteria for Adverse Events v5. Cox proportional hazard model was performed to determine factors affecting OS.RESULTS: Seventy-five BCLC-C patients treated between 2015 and 2019 were reviewed. The groups were similar in age, sex, race, and ethnicity (all p > 0.05). Bilobar disease was least common in Group 1 (p < 0.001). Median OS of the entire cohort was 13.6 (95% CI 7.5-16.1) months. Median OS of Groups 1-3 were 21.8, 13.1 and 11.5 months respectively (p = 0.6). Median PFS for the cohort was 6.3 (4.8-14.7) months. Median PFS for group 1 was not reached. Mean PFS for Group 1 was 17.3 ± 4.8 months. Median PFS for Groups 2 and 3 was 6.8 and 5.9 months (X 2 = 1.5, p = 0.5). Twenty-four Grade 3 or greater toxicities developed, most commonly hyperbilirubinemia (8/75, 11%) and thrombocytopenia (2/75, 3%). The incidence of toxicities between groups was similar (all p > 0.05). Cox Proportional Hazard analysis predicted shorter OS with CP class B/C (X 2 = 6.7, p = 0.01), while macrovascular invasion (X 2 = 0.5, p = 0.5) and ECOG score of ≥ 1 (X 2 = 2.1, p = 0.3) was not associated with OS. CONCLUSIONS: OS of CPA patients with advanced HCC and performance status of 0 was 21.8 months following Y90. CP A cirrhosis is the best predictor of prolonged OS in advanced (BCLC-C) HCC.

KW - Adult

KW - Carcinoma, hepatocellular carcinoma

KW - Treatment outcome

KW - Yttrium radioisotopes/ adverse events

KW - Yttrium radioisotopes/ therapeutic use

KW - Liver Neoplasms/pathology

KW - Carcinoma, Hepatocellular/pathology

KW - Humans

KW - Progression-Free Survival

KW - Proportional Hazards Models

KW - Cohort Studies

UR - http://www.scopus.com/inward/record.url?scp=85142149536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85142149536&partnerID=8YFLogxK

U2 - 10.1186/s12876-022-02528-y

DO - 10.1186/s12876-022-02528-y

M3 - Article

C2 - 36396989

AN - SCOPUS:85142149536

SN - 1471-230X

VL - 22

JO - BMC Gastroenterology

JF - BMC Gastroenterology

IS - 1

M1 - 467

ER -

Overall survival and toxicity of Y90 radioembolization for hepatocellular carcinoma patients in Barcelona Clinic Liver Cancer stage C (BCLC-C)

Abstract

Bibliographical note

Keywords

PubMed: MeSH publication types

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this